The FDA approved AstraZeneca’s baxdrostat (branded Baxfendy), marking the first authorization in a new aldosterone synthase inhibitor class for certain patients with hypertension. AstraZeneca said the drug is intended for use alongside other antihypertensives in people whose blood pressure remains inadequately controlled. The regulatory decision followed results from the phase 3 BaxHTN program that met both primary and secondary endpoints. Competitive attention is already shifting to Mineralys Therapeutics, which has a December 2026 PDUFA date for lorundrostat, also an aldosterone synthase inhibitor. For biotech and pharma, the approval expands the cardiometabolic pipeline into a mechanism designed to address residual hypertension despite existing standards of care, raising the bar for next-generation mineralocorticoid pathway competitors.